Daniel Rees is a partner at Latham & Watkins and a member of the firm's Corporate Department.

Mr. Rees advises clients on mergers and acquisitions and a broad range of other strategic corporate transactions. He regularly provides general representation to public and private company clients, including on corporate and securities law matters, takeover defense, and securities offerings.

Mr. Rees represents companies in the healthcare and life sciences, technology, consumer products, and real estate industries.

Mr. Rees’ experience includes the representation of:

Mergers & Acquisitions

  • Cerevel Therapeutics in its pending US$8.7 billion sale to AbbVie Inc.
  • Prometheus Biosciences in its US$10.8 billion sale to Merck 
  • Switch in its US$11 billion take-private by Digital Bridge and IFM and US$420 million acquisition of Data Foundry
  • LG Chem in its US$570 million acquisition of Aveo Oncology 
  • Funds managed by PIMCO in the US$3.9 billion acquisition of Columbia Property Trust
  • Amgen in its acquisition of Teneobio for up to US$2.5 billion in upfront cash and contingent regulatory milestones; and 20.5% stake investment in BeiGene for US$2.7 billion
  • Alastin Skincare in its sale to Galderma
  • CoStar in its acquisitions of Homesnap and Homes.com
  • Cryoport in its US$320 million acquisition of MVE Biological Solutions from Chart Industries and its US$275 million private placement of preferred and common equity with Blackstone
  • Impact Biomedicines in its sale to Celgene for up to US$7 billion in upfront cash and contingent regulatory approval and sales-based milestones
  • ICU Medical in its US$900 million acquisition of the Hospira Infusion Systems business of Pfizer
  • Air Medical Resource Group in its sale to Air Medical Group Holdings
  • Allergan in its:
    • US$40.5 billion Global Generic Pharmaceuticals Business sale to Teva
    • US$73 billion sale to Actavis
    • US$54 billion hostile takeover attempt by Valeant Pharmaceuticals International (and associated proxy contest lead by Pershing Square and Bill Ackman)
  • PIMCO in its acquisition of Gurtin Municipal Bond Management
  • ST Telemedia in CenturyLink’s US$34 billion acquisition of Level 3 Communications, Inc.
  • J.P. Morgan as financial advisor to Intralinks Holdings in its US$821 million sale to Synchronoss Technologies
  • Waypoint in its sale of its management platform to Starwood
  • Ra Pharmaceuticals in its US$2.1 billion sale to UCB
  • Akebia Therapeutics in its merger of equals with Keryx Biopharmaceuticals
  • Aratana Therapeutics in its US$234 million sale to Elanco Animal Health
  • Complete Production Services in its US$6.2 billion combination with Superior Energy Services
  • Skrewball Whiskey in its majority stake sale to Pernod Ricard
  • Golden State Foods in the sale of its McDonald’s food distribution business to Martin Brower
  • Starbucks in the US$384 million sale of its Tazo tea business
  • Incipio in its acquisition of Incase
  • 5.11 Tactical in its acquisition of Beyond Clothing
  • Paul Frank in its sale to Saban Brands
  • T. Christy Enterprises in its sale to IPS Corporation
  • California Creative Brands in its sale to Sabra

Capital Markets

  • Cryoport in its follow-on offering of common stock
  • ICU Medical in secondary offerings of common stock
  • PDL BioPharma in its equity investment in, and dividend distribution of, Evofem Biosciences
  • Landmark Infrastructure Partners LP in its IPO of common stock and other securities offerings
  • Aratana Therapeutics in its IPO of common stock
  • Skullcandy in its IPO of common stock
  • Raptor Pharmaceutical and CoreCivic in “at-the-market” offerings of common stock
  • CoreCivic in offerings of registered debt securities
  • Realty Income Corporation in equity offerings of common stock
  • CoreLogic in 144A offerings of senior notes
  • Bank of America Merrill Lynch, Citigroup, Goldman Sachs, Jefferies, J.P. Morgan, Leerink, and Piper Jaffray in follow-on offerings or IPOs, by Corium, Inogen, Glaukos, Green Plains Renewable Energy, MAKO Surgical, Sientra, and YM BioSciences

Bar Qualification

  • California


  • JD, University of California, Los Angeles School of Law, 2007
  • BS, Chapman University, 2003